Vertex’ three-drug cystic fibrosis regimen – combining the investigational next-generation corrector VX-445 with Kalydeco (ivacaftor) and tezacaftor – has achieved primary endpoints of two Phase III studies in patients the condition.
Read More
Vertex Pharmaceuticals will begin testing a combination of VX-445, tezacaftor and ivacaftor as a potential treatment for people with cystic fibrosis (CF) in two Phase III studies.
Read More
Vertex Pharmaceuticals has chosen to advance experimental therapies VX-659 and VX-445 into late stage development as part of two different triple combination regimens for people with cystic fibrosis (CF).
Read More
